Estimates
Source: S&P Capital IQ consensus via Xpressfeed · Generated 2026-07-24.
Pfizer's consensus tape pairs a steadily declining forward with a long run of upside surprises. Analysts model revenue and normalized EPS falling every year through 2029 — EPS down roughly 22% from 2026 — even as the company has beaten normalized-EPS consensus in each of the last eight quarters. Those forward estimates have barely moved over six months, so the decline reads as settled Street math rather than a fresh downgrade; ratings skew to Hold, with price targets spanning $24 to $35.
Forward estimates
Currency: USD · Scale: money in millions, absolute · YoY uses the prior fiscal year from the feed; analyst count and range use the first displayed period.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | YoY | Analysts | Low / high |
|---|---|---|---|---|---|---|---|
| Revenue | $61.75bn | $59.37bn | $54.95bn | $54.53bn | -1.3% | 25 | $59.51bn / $63.12bn |
| EPS (normalized) | $2.94 | $2.83 | $2.42 | $2.28 | -8.6% | 25 | $2.80 / $3.12 |
Normalized EPS beat consensus all eight quarters, by 4% to 73% — but the surprise is shrinking
Current sequences by metric: Revenue: 4 consecutive beats; EPS (normalized): 8 consecutive beats.
Currency: USD · Scale: money in millions, absolute · Consensus is captured before each actual first became effective.
| Quarter | Metric | Consensus | Actual | Surprise | Outcome |
|---|---|---|---|---|---|
| Q1 FY2026 | Revenue | $13.80bn | $14.45bn | +4.7% | Beat |
| Q1 FY2026 | EPS (normalized) | $0.72 | $0.75 | +3.9% | Beat |
| Q4 FY2025 | Revenue | $16.83bn | $17.56bn | +4.3% | Beat |
| Q4 FY2025 | EPS (normalized) | $0.57 | $0.66 | +16.2% | Beat |
| Q3 FY2025 | Revenue | $16.52bn | $16.65bn | +0.8% | Beat |
| Q3 FY2025 | EPS (normalized) | $0.64 | $0.87 | +37.0% | Beat |
| Q2 FY2025 | Revenue | $13.53bn | $14.65bn | +8.3% | Beat |
| Q2 FY2025 | EPS (normalized) | $0.57 | $0.78 | +35.9% | Beat |
| Q1 FY2025 | Revenue | $14.05bn | $13.71bn | -2.4% | Miss |
| Q1 FY2025 | EPS (normalized) | $0.67 | $0.92 | +36.5% | Beat |
| Q4 FY2024 | Revenue | $17.26bn | $17.76bn | +2.9% | Beat |
| Q4 FY2024 | EPS (normalized) | $0.46 | $0.63 | +37.2% | Beat |
| Q3 FY2024 | Revenue | $14.87bn | $17.70bn | +19.1% | Beat |
| Q3 FY2024 | EPS (normalized) | $0.61 | $1.06 | +73.3% | Beat |
| Q2 FY2024 | Revenue | $13.02bn | $13.28bn | +2.0% | Beat |
| Q2 FY2024 | EPS (normalized) | $0.46 | $0.60 | +30.9% | Beat |
Estimate momentum
The largest six-month change is FY2028 revenue, down about 1%.
Currency: USD · Scale: money in millions, absolute · Point-in-time consensus; Δ90d is Now versus 90d.
| Metric | FY | 180d | 90d | 30d | Now | Δ90d |
|---|---|---|---|---|---|---|
| Revenue | FY2027 | $58.97bn | $58.69bn | $59.32bn | $59.37bn | +1.2% |
| Revenue | FY2028 | $55.53bn | $54.84bn | $55.36bn | $54.94bn | +0.2% |
| EPS (normalized) | FY2027 | $2.85 | $2.82 | $2.83 | $2.83 | +0.5% |
| EPS (normalized) | FY2028 | $2.44 | $2.40 | $2.41 | $2.42 | +0.9% |
Widest disagreement is on 2027 GAAP profit and 2028 profitability, not the top line
2027 GAAP net income spans $5.7bn–$13.6bn across 8 analysts; 2028 EBITDA and normalized EPS ranges are also wide, while revenue estimates cluster tightly.
Currency: USD · Scale: money in millions, absolute · Spread/mean is absolute high-low divided by absolute mean.
| Metric | Period | Mean | Low–high | Spread/mean | Analysts |
|---|---|---|---|---|---|
| Net income (GAAP) | FY2027E | $10.27bn | $5.72bn–$13.55bn | 76.2% | 8 |
| EBITDA | FY2028E | $20.54bn | $17.54bn–$24.99bn | 36.2% | 10 |
| EPS (normalized) | FY2028E | $2.42 | $2.07–$2.97 | 37.2% | 19 |
Ratings skew to Hold — 16 of 28 — with targets from $24 to $35
Ten Buy/Outperform ratings offset two bearish; the mean target is about $29 across 26 estimates.
Currency: USD · Scale: money in millions, absolute · Analyst counts shown explicitly.
| Street view | Reading | Analysts |
|---|---|---|
| Recommendation mix | Buy 8, Outperform 2, Hold 16, Underperform 1, Sell 1 | 28 |
| Consensus score | 2.46 | 28 |
| Target price | mean $28.75; median $28.00; high $35.46; low $24.00 | 26 |
Outer-year coverage thins sharply — treat 2029 as indicative
FY2029 EBITDA carries a single estimate and GAAP net income and EPS just three each; free cash flow and net debt are means only, with no ranges.